第58届美国血液病年会关于慢性粒细胞白血病的研究精选

New advances in the study of chronic myeloid leukemia at the 58th American Society of Hematology

自酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKI）问世后,越来越多的慢性粒细胞白血病（chronic myeloid leukemia,CML）患者从中获益,且生活质量明显改善。但目前面临的不耐受、耐药、疾病进展、停药等问题,仍时刻使临床医师困惑。前不久召开的第58届美国血液病年会中,详细报道了CML相关的研究新进展,本文将其中的研究热点总结如下。

With the more experiences of tyrosine kinase inhibitors（TKI）treatment of chronic myeloid leukemia（CML）,we summarized a lot of new ideas and treatment countermeasures to the disease.This annual meeting centered on the following topics,such as the recent advances in the treatment of CML,optimizing the TKI drug conversion and the safety of TKI treatment and the sensation of TKI.Anyway,we should look forward to achieve even greater success in the treatment of CML and sum up the more precise and scientific treatment.